PREDICTIVE TECHNOLOGY GROUP ANNOUNCES LAUNCH OF PGxPLUS+™ PHARMACOGENOMIC TEST AND REACHES CLINICAL STUDY ENROLLMENT MILESTONE

Enrollment reaches 350 patients for IRB-approved study focused on chronic pain

SALT LAKE CITY (August 9, 2019) –Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories, Inc. has commercially launched PGxPLUS+, a pharmacogenomic test panel being marketed to pain clinics for patients with chronic pain.  PGxPLUS+ evaluates genetic factors that play a major role in an individual’s response to medications.  In parallel, Predictive Laboratories has reached a milestone of enrolling 350 patients with chronic pain into an Investigational Review Board-approved clinical study aimed at providing additional insight into the mechanisms of chronic pain and responses to pain therapies.

Predictive Technology Group is tackling chronic pain and the opioid crisis on multiple fronts. Predictive has already developed and in-licensed important prognostic DNA tests and novel treatments for osteoarthritis, lumbar disc disease, endometriosis, and other conditions causing chronic pain.  In 2016, the Institute of Medicine estimated that up to one-third of the U.S. population lives with ongoing pain.  Chronic pain is often triggered by one of these common conditions, and over time can develop into a chronic pain syndrome, which is a disease itself.

The PGxPLUS+ panel is one of the most comprehensive pharmacogenetic tests available on the market.  Predictive’s test evaluates 112 genetic variants across 38 genes that affect the metabolism of over 150 common medications, including pain medications.  More than 90% of the population has one or more gene variants that affect the efficacy or safety of prescription drugs.  Variation in drug metabolism is largely determined by an individual’s genetic profile, blood levels of a drug may vary up to 1,000-fold in similar patients taking identical doses of the same drug.  Pharmacogenomics is the study of the role of our genome in drug responses.

Dr. Bryt Christensen, M.D., a pain specialist, reports, “The PGxPLUS+ pharmacogenetic test has been very helpful in my day-to-day practice.  The results give insights into why some patients are not responding to medications as expected.  With the help of these test results, I have been able to start or switch medications for patients more successfully.  The PGxPLUS+ test helps me avoid prescribing medications that a patient won’t metabolize well, leading to better and more personalized patient care.” 

One-third of patients taking long-term opioid therapy for non-cancer chronic pain either find their medication to be ineffective or they do not tolerate the side effects of the treatment. In the clinical study, Predictive is testing patients who are taking high doses of opioids [≥50 morphine milligram equivalents (MME)/day] for genetic variants responsible for their underlying disease, their metabolism of opioids, their intrinsic pain thresholds, and any genetic predisposition to opioid addiction.  Predictive plans to develop more comprehensive treatment guidelines for pain based on predictive genetic markers. 

“The ability to effectively treat individuals in pain represents a significant market opportunity and of even greater importance it serves an obligation of society to alleviate the current pain and suffering of an individual in a safer and more effective manner,” said Bradley Robinson, CEO of Predictive Technology Group.  “Our Company is both identifying the most effective ways to treat pain at a personalized level and working to understand the underlying cause of diseases like osteoarthritis, lumbar disc disease and endometriosis to treat or prevent the root cause of the pain.  We are pleased to add the PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic products focused on treating chronic pain diseases.”

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contacts: For more information, visit www.predtechgroup.com

ELEMENT GLOBAL, INC.’S (ELGL) BOARD OF DIRECTORS APPOINTS TWO NEW CORPORATE OFFICERS

Los Angeles, CA- August 8, 2019- Element Global, Inc. (ELGL: OTCMarkets) announces the new appointment of two corporate officer positions, CEO and President. 

ELGL’s Board of Directors, according to the terms and conditions of the recent asset acquisitions, appointed and approved both Mr. John LaViolette as ELGL’s Chief Executive Officer and Mr. Sasha Shapiro as President.

Mr. LaViolette’s and Mr. Shapiro’s years of experience and business relationships in all facets of ELGL’s core businesses can assure the development, growth, and scale at the Company.

Merle Ferguson, the Chairman, states, “the talent and skill-sets of both Mr. LaViolette and Mr. Shapiro bring experience to the ELGL team, adding to the Company’s business successes now and in the future.”

Over the next 90-day’s ELGL expects to bring aboard a highly qualified senior management team and advisory board.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

ELEMENT GLOBAL, INC. (ELGL) ACQUIRES ELEMENT INTERNATIONAL GROUP ‘S ASSETS

Los Angeles, CA- August 6, 2019- Element Global, Inc. (ELGL:OTCPINK) announces completing the acquisition of Element International Group’s corporate assets and operations.

Element International Group contained assets and operations of Element Media Group, Element Global Mining Enterprises, Element Technology, and Element Energy.  As of today, Element Global, Inc. (ELGL) now holds these assets and operations. 

As a holding Company, Element Global, Inc. expects to grow operations, build brand awareness, develop new products and markets, and maximize the assets to their full potential. 

Merle Ferguson, Chairman, states, “After years of negotiations, the assets of Element International Group are now under the control of ELGL. We expect these assets to be accretive to the Company’s financial growth of its operations.”

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.elementglobal.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Predictive Technology Group Names Industry Veteran Dr. E. Robert Wassman Co-Laboratory Director of Predictive Laboratories

Dr. Wassman brings 35 years of genetics diagnostic and personalized medicine experience, and significant expertise to lead the cytogenetics section of Predictive Laboratories

SALT LAKE CITY (August 6, 2019) –Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the appointment of E. Robert Wassman, M.D. as Co-Laboratory Director of Predictive Laboratories. 

Dr. Wassman has been pioneering the introduction of genetic testing and personalized medicine for over 35 years. Throughout his career, he has focused on the translation and delivery of cutting-edge diagnostic technology to clinical services in the areas of reproductive medicine, rare cell/non-invasive diagnostics, and next-generation DNA sequencing. He brings Predictive Laboratories critical expertise in reproductive genetics, cancer and companion diagnostics, and neurodevelopmental disabilities including autism. Dr. Wassman is a graduate of Yale University and Albany Medical College and he is Board Certified in Pediatrics and Medical Genetics.

Dr. Wassman previously served as Chief Medical Officer for multiple companies in the genetic testing space including Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health, Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics and Alfigen. He co-founded several successful ventures and served as a consultant to a wide variety of entities ranging from large to small clinical laboratories, IVD and biotech companies, investment groups, regulatory agencies, payers and legal firms.

In addition to clinical and technical expertise, Dr. Wassman has laboratory and general operational, business development, medical affairs/marketing and sales experience in the U.S., Europe, Japan and China. He has formal training and both public and private sector experience in reimbursement and managed care. Dr. Wassman currently serves on the Board of Directors and Scientific Advisory Board of the TESS Foundation, a non-profit focused on treatments for epilepsy and symptoms of SLC13A5 epileptic encephalopathy.

“We are delighted that Dr. Wassman is joining our outstanding team at Predictive Laboratories,” said Bradley Robinson, CEO of Predictive Technology Group. “Dr. Wassman’s strategic insights, deep scientific and medical knowledge, and quick study abilities have enabled him to play a pivotal role in numerous firsts in reproductive genetics including expanded maternal serum screening, the first nationwide Pre-Implantation Genetic (PGD) test, and the first commercially successful clinical NGS-based testing for carrier screening in IVF clinics. We welcome him to Predictive Laboratories and look forward to his contributions as we expand our genetic-based diagnostics.”

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contacts: For more information, visit www.predtechgroup.com 

Predictive Laboratories to Present New Endometriosis Discoveries in Three Presentations at Leading Scientific Conference Focused on Human Infertility

American Society of Reproductive Medicine selects findings through scientific peer-review process for presentations at the 75th ASRM Scientific Congress & Expo in October

SALT LAKE CITY (August 2, 2019) – Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), announces the presentation of new genetic findings in endometriosis at the 75th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo being held October 12-16, 2019 in Philadelphia. The new findings will be presented by Predictive Laboratories’ scientific team. Predictive Technology Group is a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention.

Three scientific presentations (two oral and one poster) highlighting recent discoveries by Predictive Laboratories were selected through ASRM’s scientific peer-review process. The presentations will focus on several features of endometriosis, including genetic mechanisms underlying the disorder, potential disease gene interactions, and the mechanisms through which some benign endometriosis lesions might become cancerous. The content of these presentations is embargoed until data are presented at the conference. Patent applications have been filed around these new discoveries adding to the Company’s robust endometriosis patent portfolio.

Endometriosis affects more than 10 million women in the United States. It occurs when tissue similar to the lining of the uterus (womb) appears in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others have problems with their menstrual periods, and some have no symptoms at all. Treatment may involve hormonal suppression or surgical destruction of the abnormal tissue.

“We are very pleased with the acceptance of these presentations by ASRM and to be presenting this important data to the thousands of researchers and physicians attending the ASRM meetings,” said Bradley Robinson, CEO of Predictive Technology Group. “Most importantly we look forward to these discoveries being applied in clinical settings to reduce the suffering of millions of women around the world and aiding to eliminate or reduce the related complications of this debilitating disease. 

“We look forward to announcing these data following the presentations at ASRM meeting,” he added.  “I’m delighted with the commitment of our scientific team and its dedication in continuing to expand the understanding of endometriosis.”  

The Company’s population genetics research underlies its novel ARTGuide™ test, a first-of-its-kind non-invasive diagnostic test for endometriosis and other genetic causes of infertility currently launched to select collaborators by Predictive Laboratories.  

ASRM is an international and multi-disciplinary organization devoted to advancing knowledge and expertise in reproductive medicine and biology, with a particular focus on human infertility.

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.comPredrx.comPredictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contacts: For more information, visit www.predtechgroup.com

ELEMENT GLOBAL, INC. (ELGL) ANNOUNCES LOCATION OF NEW CORPORATE OFFICE

Los Angeles, CA- August 1, 2019- Element Global, Inc. (OTC MARKETS: ELGL) announces its new office location at 6555 Barton Ave, 2nd Floor, Los Angeles, CA. The new site provides excellent accessibility, room for growth and approximately 15 miles from the Los Angeles International Airport.

After successfully moving from Virginia Beach, Virginia, Element Global’s official opens today, August 1, 2019.

Merle Ferguson, the Chairman, states, “The new office, nicely located in Hollywood, gives us a professional image and provides a location near major entities in the media and movie industries.”

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090, yes@yesinternational.com and www.yesinternational.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition

Predictive Laboratories Announces Research Collaboration with the Preeclampsia Foundation

Collaboration to expand the study of genetic factors contributing to preeclampsia and support Predictive Laboratories’ development of personalized products to detect preeclampsia risk before and during pregnancy

SALT LAKE CITY, UT- July 31, 2019 –  Predictive Technology Group, Inc. (OTCPINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces that its wholly owned subsidiary Predictive Laboratories has entered into a research collaboration with the Preeclampsia Foundation to expand the study of genetic factors associated with preeclampsia. The study will advance the Preeclampsia Foundation’s database of collected preeclampsia medical information and will be utilized by Predictive Laboratories to develop a proprietary test for the early detection of women at risk for preeclampsia.

Preeclampsia affects 5-8%, or approximately 300,000, pregnancies every year in the United States, sometimes causing severe adverse maternal and fetal outcomes, including organ failure, massive blood loss, permanent disability or even death. Globally, preeclampsia is a leading cause of pregnancy complications, preterm births and related disabilities. The deaths of approximately 76,000 mothers and 500,000 babies annually are attributable to preeclampsia. Healthcare providers, even in medically advanced countries, are hampered by imprecise diagnostic tools.

The Preeclampsia Registry, a key program of the Preeclampsia Foundation’s research mission, is a patient registry that collects paired medical information and biological samples. Using established Institutional Review Board-approved protocols, Predictive Laboratories and the Preeclampsia Foundation will request samples from more than 2,500 existing and new registry participants for sequencing analysis. Predictive Laboratories has been granted a period of exclusive access to research data resulting from these new samples enrolled in the Preeclampsia Registry, after which samples and sequencing data will be available to other investigators for future research.

“The Preeclampsia Foundation created an empowered community of patients and experts with a diverse array of resources, support and advocacy to help women have the best possible outcomes from their pregnancies,” said Bradley Robinson, CEO of Predictive Technology Group. “We look forward to enhancing our partnership, helping to grow the Preeclampsia Registry resource and developing innovative and effective products aimed at the early detection and treatment of this devastating medical condition.”

This collaboration complements and extends ongoing preeclampsia research initiatives at Predictive Laboratories. Over 20,000 DNA samples from Predictive’s biorepository relating to preeclampsia and associated obstetric syndromes are being analyzed. Predictive Laboratories’ pending patent applications relating to predictive genetic markers of preeclampsia were acquired through its acquisition of Taueret Laboratories, which was completed in March 2019. Prior to acquisition, the Taueret Laboratories team had a long history of collaboration with the Preeclampsia Foundation and invested significant resources towards genotyping and sequencing thousands of samples during discovery work. The combination of knowledge and resources under the Predictive Laboratories subsidiary represents a strong pipeline for developing novel DNA based products.

“We envision a world where preeclampsia no longer threatens the lives of mothers and their babies,” said Eleni Tsigas, CEO of the Preeclampsia Foundation. “In addition to a diagnostic test Predictive Laboratories may develop, this infusion of genomic data to our already robust registry accelerates our research agenda and brings us closer to making our vision a reality.”

About the Preeclampsia Foundation
Established in 2000, the Preeclampsia Foundation is the only 501(c)(3) not-for-profit patient advocacy organization representing the 5-8% of pregnant women and their babies who are affected by life-threatening hypertensive disorders of pregnancy, such as preeclampsia, eclampsia, and HELLP syndrome. The Foundation is advised by a medical board comprised of top medical and scientific experts and works collaboratively with many other stakeholders to achieve its mission of improving the outcomes of hypertensive disorders of pregnancy by educating, supporting and engaging the community, improving healthcare practices, and finding a cure. Additional information is available at Preeclampsia.org and Preeclampsiaregistry.org.

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.comPredrx.comPredictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contact: For more information, visit www.predtechgroup.com

ELEMENT GLOBAL, INC. (ELGL) ANNOUNCES TWO APPOINTMENTS TO ITS BOARD OF DIRECTORS; BEGINS BUILDING NEW WEBSITE

July 30, 2019- Virginia Beach, VA- Element Global Inc. (ELGL: OTCMarkets) announces the appointment of two new members to its Board of Directors, John LaViolette and Sasha Shapiro.

Mr. John LaViolette, Co-Founder and Co-CEO of Element International Group, Inc. and a senior partner in the entertainment law firm of Bloom, Hergott, Diemer, Rosenthal, LaViolette, Feldman, Schenkman & Goodman LLP, maintains extensive relations with all major Hollywood studios and networks. Mr. LaViolette represents a vast number of “A-list” actors, writers, and directors.

Mr. Sasha Shapiro, a Managing Director of QED and Covert Media, also, manages Media Content Capital’s private equity investment fund which focuses on early/medium-stage investments into media, internet, and entertainment companies. With over 25 years of experiences in the global media and entertainment industries, he held senior management positions at Warner Bros. Studios and Pacifica Ventures and consulted for world-renowned media companies such as Gazprom-Media (Russia), Imax, RealD, and Lenfilm (oldest Russian Film/TV studio). At Warner Bros., Mr. Sharpio’s responsibilities included the development of new market entries, strategic planning, financial evaluation, and implementation of new business opportunities in all major foreign markets.

Merle Ferguson, Chairman of Element Global, Inc., states, “the addition of both Mr. LaViolette and Mr. Shapiro to ELGL’s Board of Directors brings an enormous acumen to the Company’s current and future growth proposition. I’m looking forward to working with them both in the global growth strategies ahead for the Company.”

Currently, “Under Construction,” the Company now controls the website, www.elementglobal.com.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090, yes@yesinternational.com and www.yesinternational.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Contact:

Rich Kaiser

YES INTERNATIONAL

757-306-6090

Covalent Collective, Inc. Submits Requested Documents to SEC

Founder Geoffrey Thompson Resigns from Company

COLORADO SPRINGS, CO- July 26, 2019 – Covalent   Collective, Inc. (the “Company”), a burgeoning network of vertically integrated cannabis-centric enterprises, announced today that it has submitted all of the documents in its possession, custody or control that relate to the subpoena issued against the Company by the United States Securities and Exchange Commission (SEC) on October 24, 2018.

“On July 23 we produced all of the documents we believe were necessary to comply with the SEC’s subpoena,” commented Mr. Bill Gregorak, CEO of Covalent Collective.  “While we must hold ourselves accountable for missing the initial deadline, once we fully understood what was required by the SEC, we were able to fulfill our obligations and submit a detailed response ahead of the deadline.  Although we won’t know if the SEC is satisfied with the content of our submission until a later date, we believe that the significant volume of correspondence and documentation we produced included everything called for by the subpoena,” Mr. Gregorak continued.

Separately, the Company announced today that its founder Geoffrey Thompson has resigned from his positions as a director and officer of the Company and its various subsidiaries and agreed to relinquish all associated corporate responsibilities effective immediately.

About Covalent Collective:

Covalent Collective, Inc. is a British Columbia, Canada company founded in 2014 and headquartered in Colorado Springs, CO. The Company is building a diverse network of vertically integrated cannabis-centric enterprises that span the entirety of the legal cannabis and hemp industries. With a vision to build the largest grow capacity in the U.S., Covalent Collective’s mission is to create stronger bonds throughout the greater cannabis community through the execution of an acquisition and joint venture strategy that is strategically positioned to support eventual federal legalization in the United States. For more information, please visit https://covalentcannabis.com.

Cautionary Note Regarding Forward-Looking Statements:


This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements with respect to the Company’s acquisition strategies. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievements could differ materially from those expressed in, or implied by, any forward-looking statements in this press release, and readers should not place undue reliance on any such forward-looking statements since they are not guarantees of future results. The Company does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

Richard Kaiser

Covalent Collective, Inc.

rkaiser@covalentcannabis.com

757-306-6090

Predictive Technology Group announces its 11th Consecutive Quarter of Revenue Growth

Affirms business strategy and milestones

SALT LAKE CITY (July 15, 2019) – Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the continuation of consecutive quarter revenue growth for the fiscal 2019 fourth quarter ended June 30, 2019.

“We are proud of our revenue growth, fundamentals and business momentum. We continue to make excellent progress with our strategy to increase sales from our human cell and tissue products, while preparing for the full commercial launch in the coming quarters of our genetic-based endometriosis and fertility diagnostic/prognostic tests,” said Bradley Robinson, CEO of Predictive Technology Group.

“Over the past several months we made significant strides in building a strong infrastructure,” Robinson added. “We strengthened our executive leadership and our board of directors, announced a key global collaboration with Thermo Fisher Scientific to better understand the genetic factors underlying infertility, and presented new genetic data at key industry conferences. We also completed the integration of two DNA laboratories into Predictive Laboratories at a much faster pace than anticipated, and appointed experienced industry veterans to lead this state-of-the-art facility. Additionally, we filed a Form 10 with the United States Securities and Exchange Commission (US SEC) that is effective, making Predictive Technology Group a full reporting 1934 Exchange Act compliant company. And, we submitted an application, which is currently under review, to list Predictive Technology Group’s common stock for trading on The NASDAQ Stock Market.”

The Company expects to report its fourth quarter and fiscal 2019 full year financial results in September 2019. 

Predictive is aware that a short-seller recently issued a critical opinion piece regarding the Company in an attempt to manipulate the Company’s stock price.  “This opinion piece was produced by anonymous author(s) who admit in the opinion piece that they ‘have taken a really large short position in shares’ of our Company and ‘stand to benefit financially if the stock price declines,’” said John Sorrentino, Chairman of Predictive Technology Group.  “As stated in the short-seller opinion’s disclaimers, the anonymous authors refuse to stand behind their allegations – they make ‘no representation, express or implied, as to the accuracy, timeliness, or completeness of [the opinion’s] information. . .’   Given that the short-seller opinion is intended to drive down the price of the Company’s stock and the opinion’s authors have refused to guarantee the accuracy of the ‘information’ the opinion espouses, the Company will not dignify the opinion piece with a point-by-point response. The Company remains focused on developing products that have the potential to improve the quality of life for people throughout the world.”

The Company notes, however, that some of the topics raised in the piece – including the Company’s recent acquisitions – are fully disclosed, in detail, in the Company’s filings with the US SEC.  The Company encourages stakeholders to review the detail of these transactions in its US SEC Edgar filings.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.comPredrx.comPredictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contact:

For more information, visit www.predtechgroup.com